群益证券：维持复星医药(02196)“买进”评级目标价26.5港元

智通财经10-29

智通财经APP获悉，群益证券发布研报称，预计复星医药(02196)2025-2027年实现净利润33.2亿元、39.6亿元、47.7亿元，YOY分别+19.9%、+19.4%、+20.4%，EPS分别为1.2元、1.5元、1.8元，对应H股PE分别为17X/14X//12X，短期研发费用增加虽影响净利端表现，但长期来看，创新药持续带动业绩增长，BD交易重塑管线价值，股权激励业绩考核保底业绩增速，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2579923979?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-29 14:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579923979","market":"hk","top_or_hot":-1,"title":"群益证券：维持复星医药(02196)“买进”评级 目标价26.5港元","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，群益证券发布研报称，预计复星医药(02196)2025-2027年实现净利润33.2亿元、39.6亿元、47.7亿元，YOY分别+19.9%、+19.4%、+20.4%，EPS分别为1.2元、1.5元、1.8元，对应H股PE分别为17X/14X//12X，短期研发费用增加虽影响净利端表现，但长期来看，创新药持续带动业绩增长，BD交易重塑管线价值，股权激励业绩考核保底业绩增速，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1361931.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>群益证券：维持复星医药(02196)“买进”评级 目标价26.5港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n群益证券：维持复星医药(02196)“买进”评级 目标价26.5港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-29 14:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1361931.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，群益证券发布研报称，预计复星医药(02196)2025-2027年实现净利润33.2亿元、39.6亿元、47.7亿元，YOY分别+19.9%、+19.4%、+20.4%，EPS分别为1.2元、1.5元、1.8元，对应H股PE分别为17X/14X//12X，短期研发费用增加虽影响净利端表现，但长期来看，创新药持续带动业绩增长，BD交易重塑管线价值，股权激励业绩考核保底业绩增速，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1361931.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"161027","symbol_name":"证券","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1361931.html","article_id":"2579923979","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579923979","pubTimestamp":1761718598,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"群益证券主要观点如下：公司业绩公司25Q1-Q3实现营收293.9亿元，录得归母净利润25.2亿元，YOY+25.5%，扣非后归母净利润15.7亿元。集采影响总体营收，创新产品延续较快增长公司2025年前三季度及Q3单季营收均有小幅负增长，主要是仿制药品受到药品集中带量采购续标以及部分地方药品集中带量采购的影响，但前三季度创新药保持较快增长，前三季度创新药收入超67亿，同比增长18.1%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"161027":"证券","600196":"复星医药","02196":"复星医药"},"translate_title":"Qunyi Securities: Maintain Fosun Pharma (02196) \"buy\" rating with a target price of HK $26.5","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1.5,"600196":1.5,"02196":1.5},"content_text":"智通财经APP获悉，群益证券发布研报称，预计复星医药(02196)2025-2027年实现净利润33.2亿元、39.6亿元、47.7亿元，YOY分别+19.9%、+19.4%、+20.4%，EPS分别为1.2元、1.5元、1.8元，对应H股PE分别为17X/14X//12X，短期研发费用增加虽影响净利端表现，但长期来看，创新药持续带动业绩增长，BD交易重塑管线价值，股权激励业绩考核保底业绩增速，该行维持A/H股“买进”的投资评级，目标价26.5港元。群益证券主要观点如下：公司业绩公司25Q1-Q3实现营收293.9亿元，录得归母净利润25.2亿元，YOY+25.5%，扣非后归母净利润15.7亿元。分季度来看，公司Q3单季度实现营收98.8亿元，录得归母净利润8.2亿元，YOY+4.5%，扣非后归母净利润6.1亿元，YOY+5.2%。集采影响总体营收，创新产品延续较快增长公司2025年前三季度及Q3单季营收均有小幅负增长，主要是仿制药品受到药品集中带量采购续标以及部分地方药品集中带量采购的影响，但前三季度创新药保持较快增长，前三季度创新药收入超67亿，同比增长18.1%。Q3公司持续推进创新品上市，9月创新型小分子CDK4/6抑制剂复妥宁在国内新获批一适应症，HLX14地舒单抗注射液于9月先后获获批在美国、欧盟上市，FKC889布瑞基奥仑赛注射液也已在国内申报上市，9月获得国家药监局受理，该行认为随着公司创新药产品的陆续上市，将会推动营收端回升。Q3毛利率微升，研发费用同比增加较多公司Q3单季度综合毛利率为48.4%，同比提升0.3个百分点，主要受益于高毛利率创新药产品占比提升推动，Q3期间费用率为44.1%，同比增1.4个百分点，其中销售费用率下降1.4个百分点，管理费用率增0.2个百分点，财务费用率同比下降0.8个百分点，研发费用率大幅增加2.7个百分点，同比增加2.2亿元，主要是公司增加投资于包括核药、细胞治疗在内的创新平台，以及HLX22、HLX43等高价值管线的全球多中心临床。风险提示：新产品研发进度及销售不及预期，药品集采及国谈降价超预期，商誉减值风险","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579923979","isCrawlerRequest":true}

群益证券：维持复星医药(02196)“买进”评级 目标价26.5港元

精彩评论

群益证券：维持复星医药(02196)“买进”评级目标价26.5港元